title: Advanced glycation end products contribute to the immunogenicity of IFN-β pharmaceuticals.
authors.forename: Angelina
authors.initials: A
authors.lastname: Bozhinov
authors.forename: Yordan
authors.initials: Y
authors.lastname: Handzhiyski
authors.forename: Krasimir
authors.initials: K
authors.lastname: Genov
authors.forename: Vera
authors.initials: V
authors.lastname: Daskalovska
authors.forename: Toshimitsu
authors.initials: T
authors.lastname: Niwa
authors.forename: Ivan
authors.initials: I
authors.lastname: Ivanov
authors.forename: Roumyana
authors.initials: R
authors.lastname: Mironova
mesh_terms: D000328:Adult; D000818:Animals; D057134:Antibodies, Neutralizing / Q000096:biosynthesis; D016466:CHO Cells; D006224:Cricetinae; D004797:Enzyme-Linked Immunosorbent Assay; D004926:Escherichia coli; D005260:Female; D017127:Glycation End Products, Advanced / Q000276:immunology* / Q000378:metabolism; D006031:Glycosylation; D006241:Haptens / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007093:Imidazoles / Q000378:metabolism; D007167:Immunotherapy; D016899:Interferon-beta / Q000008:administration & dosage / Q000276:immunology* / Q000378:metabolism; D008239:Lysine / Q000031:analogs & derivatives / Q000378:metabolism; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology; D011499:Protein Processing, Post-Translational; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology* / Q000378:metabolism
chemical_list: D057134:Antibodies, Neutralizing; D017127:Glycation End Products, Advanced; D006241:Haptens; D007093:Imidazoles; D011994:Recombinant Proteins; C117197:imidazolone; C048496:N(6)-carboxymethyllysine; D016899:Interferon-beta; D008239:Lysine